Luana Gonçalves de Souza

Dr. Luana Gonçalves de Souza

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in Journal of Natural Products
Verified
Journal Article
Closed access
Guilherme S. CaleffiGuilherme S. Caleffi
Guilherme S. Caleffi
ARAlice S. Rosa
Alice S. Rosa
LSLuana Gonçalves de Souza
Luana Gonçalves de Souza
JAJoão L. S. Avelar
João L. S. Avelar
SNSarah M. R. Nascimento
Sarah M. R. Nascimento
PCPaulo Costa
Paulo Costa

4 December 2023 in Archiv der Pharmazie
Verified
Journal Article
Closed access
NONathalia S. de Oliveira
Nathalia S. de Oliveira
LSLuana Gonçalves de Souza
Luana Gonçalves de Souza
VAVitor Martins de Almeida
Vitor Martins de Almeida
ABArielly R. R. Barreto
Arielly R. R. Barreto
FCFelipe Carvalho‐Gondim
Felipe Carvalho‐Gondim
ASAlcides J. M. Da Silva
Alcides J. M. Da Silva

26 February 2023 in Journal of Molecular Structure
Verified
Journal Article
Closed access
DLDaiene Lapa
Daiene Lapa
LSLuana Gonçalves de Souza
Luana Gonçalves de Souza
ESEdgar Schaeffer
Edgar Schaeffer
EJEunice C. de Jesus
Eunice C. de Jesus
AVAndré A. Vieira
André A. Vieira
ASAlcides J. M. Da Silva
Alcides J. M. Da Silva

13 November 2024 in Viruses
Verified
Journal Article
Open access
PDF file
LSLuana Gonçalves de Souza
Luana Gonçalves de Souza
EPEduarda A. Penna
Eduarda A. Penna
ARAlice dos Santos Rosa
Alice dos Santos Rosa
JSJuliana C. da Silva
Juliana C. da Silva
ESEdgar Schaeffer
Edgar Schaeffer
ASAlcides J. M. Da Silva
Alcides J. M. Da Silva
Endemic and pandemic viruses represent significant public health challenges, leading to substantial morbidity and mortality over time. The COVID-19 pandemic has underscored the urgent need for the development and discovery of new, potent antiviral agents. In this study, we present the synthesis and anti-SARS-CoV-2 activity of a series of benzocarbazoledinones, assessed using cell-based screening assays. Our results indicate that four compounds (4a, 4b, 4d, and 4i) exhibit EC50 values below 4 μM without cytotoxic effects in Calu-3 cells. Mechanistic investigations focused on the inhibition of the SARS-CoV-2 main protease (Mpro) and papain-like protease (PLpro) have used enzymatic assays. Notably, compounds 4a and 4b showed Mpro inhibition activity with IC50 values of 0.11 ± 0.05 and 0.37 ± 0.05 µM, respectively. Furthermore, in silico molecular docking, physicochemical, and pharmacokinetic studies were conducted to validate the mechanism and assess bioavailability. Compound 4a was selected for preliminary drug-likeness analysis and in vivo pharmacokinetics investigations, which yielded promising results and corroborated the in vitro and in silico findings, reinforcing its potential as an anti-SARS-CoV-2 lead compound.

3 April 2025 in Journal of Molecular Structure
Verified
Journal Article
Closed access
LSLuana Gonçalves de Souza
Luana Gonçalves de Souza
LOLuiz Fernando Silva Oliveira
Luiz Fernando Silva Oliveira
DPDanilo Predes
Danilo Predes
MRMagdalena N. Renno
Magdalena N. Renno
JAJose G.R. Abreu
Jose G.R. Abreu
PCPaulo R.R. Costa
Paulo R.R. Costa

1 January 2023 in Revista Virtual de Química
Verified
Journal Article
Closed access
LSLuana Gonçalves de Souza
Luana Gonçalves de Souza
MRMagdalena Nascimento Rennó
Magdalena Nascimento Rennó
PCPaulo Costa
Paulo Costa